Clinical experiences with ruxolitinib in symptomatic patients with myeloproliferative neoplasm with chronic kidney disease

Leuk Lymphoma. 2014 Jan;55(1):213-6. doi: 10.3109/10428194.2013.797086. Epub 2013 Jun 12.

Authors

Ali Tabarroki¹, Valeria Visconte, Heesun J Rogers, Mikkael A Sekeres, Christy Samaras, Alan Lichtin, Hien K Duong, Ricki Englehaupt, Tracy Cinalli, Kristin Dodd, John Desamito, Basel Rouphail, Jessica K Altman, Brady L Stein, Ramon V Tiu

Affiliation

¹ Department of Translational Hematology and Oncology Research.

PMID: 23607256
DOI: 10.3109/10428194.2013.797086

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents / therapeutic use*
Fatal Outcome
Female
Humans
Male
Middle Aged
Myeloproliferative Disorders / complications*
Myeloproliferative Disorders / diagnosis
Myeloproliferative Disorders / drug therapy*
Nitriles
Pyrazoles / therapeutic use*
Pyrimidines
Renal Insufficiency, Chronic / complications*
Renal Insufficiency, Chronic / diagnosis
Treatment Outcome

Substances

Antineoplastic Agents
Nitriles
Pyrazoles
Pyrimidines
ruxolitinib